New trial launches to identify ways to prevent recurrence of colorectal cancer

To address concerns of colorectal cancer recurring after initial treatment, the National Cancer Institute, in collaboration with SWOG, one of the five cooperative groups that together will comprise NCI's National Clinical Trials Network, and Cancer Prevention Pharmaceuticals, Inc., recently announced a phase III trial. The Preventing Adenomas of the Colon with Eflornithine & Sulinidac (PACES) trial looks at whether someone who has been treated for colon cancer in the past can lower his or her risk of having a second primary colorectal cancer or an adenoma (a type of polyp on the colon wall that may be precancerous) by regularly taking one or both of the study drugs, eflornithine and sulindac. Read more here.